Evidence map›Paper›PMID 38700450›Full record

ArticleAdvanced healthcare materials2024

Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.

Niranjan Meher, Gary W Ashley, Kondapa Naidu Bobba, Anju Wadhwa, Anil P Bidkar, Chandrashekhar Dasari, Changhua Mu, Ramya Ambur Sankaranarayanan, Juan A Camara Serrano, Athira Raveendran and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Niranjan MeherDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA.ORCID 0000-0003-3558-3712
Gary W AshleyProLynx Inc., San Francisco, CA, 94158, USA.
Kondapa Naidu BobbaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA.
Anju WadhwaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA.
Anil P BidkarDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA.
Chandrashekhar DasariHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143-0981, USA.
Changhua MuDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA.
Ramya Ambur SankaranarayananDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA.
Juan A Camara SerranoDivision of Vascular and Endovascular Surgery, University of California, San Francisco, CA, 94143-0957, USA.
Athira RaveendranDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA.
David P BulkleyDepartment of Pathology, University of California, San Francisco, CA, 94143, USA.
Rahul AggarwalDivision of Vascular and Endovascular Surgery, University of California, San Francisco, CA, 94143-0957, USA.
Nancy Y GreenlandDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, 94158-2517, USA.
Adam OskowitzHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143-0981, USA.
David M WilsonDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA.
Youngho SeoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA.
Daniel V SantiProLynx Inc., San Francisco, CA, 94158, USA.
Henry F VanBrocklinDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA.
Robert R FlavellDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA.ORCID 0000-0002-8694-1199

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7M
Molecular imaging of novel PARP inhibitor nanomedicine deliveryR01CA266666 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGGARWAL, RAHUL, FLAVELL, ROBERT RICHARD · 2022 to 2025
$2.4M
Combined dual-modality SPECT/CT for small animal imaging research at UCSFS10OD012301 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEO, YOUNGHO · 2015 to 2015
$1.2M
NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA266666NIH HHS S10 OD012301Science, Mathematics, And Research For Transformation Scholarship Program S10OD012301U. S. Department of Energy
6 · The paper itself

Abstract

The tumor uptake of large non-targeted nanocarriers primarily occurs through passive extravasation, known as the enhanced permeability and retention (EPR) effect. Prior studies demonstrated improved tumor uptake and retention of 4-arm 40 kDa star polyethylene glycol (StarPEG) polymers for cancer imaging by adding prostate-specific membrane antigen (PSMA) targeting small molecule ligands. To test PSMA-targeted delivery and therapeutic efficacy, StarPEG nanodrugs with/without three copies of PSMA-targeting ligands, ACUPA, are designed and synthesized. For single-photon emission computed tomography (SPECT) imaging and therapy, each nanocarrier is labeled with 177Lu using DOTA radiometal chelator. The radiolabeled nanodrugs, [177Lu]PEG-(DOTA)1 and [177Lu]PEG-(DOTA)1(ACUPA)3, are evaluated in vitro and in vivo using PSMA+ PC3-Pip and/or PSMA- PC3-Flu cell lines, subcutaneous xenografts and disseminated metastatic models. The nanocarriers are efficiently radiolabeled with 177Lu with molar activities 10.8-15.8 MBq/nmol. Besides excellent in vitro PSMA binding affinity (kD = 51.7 nM), the targeted nanocarrier, [177Lu]PEG-(DOTA)1(ACUPA)3, demonstrated excellent in vivo SPECT imaging contrast with 21.3% ID/g PC3-Pip tumors uptake at 192 h. Single doses of 18.5 MBq [177Lu]PEG-(DOTA)1(ACUPA)3 showed complete resolution of the PC3-Pip xenografts observed up to 138 days. Along with PSMA-targeted excellent imaging contrast, these results demonstrated high treatment efficacy of [177Lu]PEG-(DOTA)1(ACUPA)3 for prostate cancer, with potential for clinical translation.

Indexed as

Glutamate Carboxypeptidase IIPolyethylene GlycolsProstatic NeoplasmsTomography, Emission-Computed, Single-PhotonAnimalsAntigens, SurfaceCell Line, TumorDrug CarriersHeterocyclic Compounds, 1-RingHumansLutetiumMaleMiceMice, NudeNanoparticlesRadioisotopesAntigens, SurfaceDrug CarriersFOLH1 protein, humanGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingLutetiumLutetium-177Polyethylene GlycolsRadioisotopesenhanced permeability and retentionpolymer nanocarriersprostate cancerprostate‐specific membrane antigen (PSMA)radioligand therapysingle photon excited computed tomography (SPECT) imaging

Identifiers

PMID38700450
PMCPMC11281871

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.